arvelle triangle

ARVELLE
IN THE NEWS

Appointment of Dr Otto Schwarz as Independent Director and Chairman of the Board

Zug, Switzerland, December 4, 2019 – Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, today announces that Dr Otto Schwarz will join the Board of Arvelle Therapeutics as an Independent Director and serve as Chairman of the Board, with immediate effect. Dr Otto Schwarz

read more >


SK Life Science, Inc. Receives US FDA Approval for cenobamate tablets for the Treatment of Partial-Onset Seizures in Adults with Epilepsy

Approval based on pivotal trials that assessed the efficacy and safety of cenobamate Arvelle Therapeutics has exclusive rights to develop and commercialize cenobamate in Europe Arvelle Therapeutics plans to submit a Marketing Authorization Application in Europe in H1 2020 Zug, Switzerland, November 25, 2019 – Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing

read more >


Arvelle Therapeutics wins Series A Finance Raise of the Year Award

Zug, Switzerland, November 20, 2019 – Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to patients with CNS disorders, is pleased to announce that Arvelle has won the 2019 Lifestars “Series A Finance Raise of the Year” Award. Mark Altmeyer, President and CEO of Arvelle Therapeutics, said: “We are delighted to

read more >


Results of Randomized Study Evaluating the Safety and Efficacy of Cenobamate in Patients with Uncontrolled Focal-Onset Epilepsy Published in The Lancet Neurology

Cenobamate significantly reduced focal seizure frequency, with as many as 20% of patients reaching zero seizures during the study’s maintenance phase Zug, Switzerland, November 14, 2019 – Arvelle Therapeutics GmbH, an emerging biopharmaceutical company focused on bringing innovative treatments to patients with CNS disorders, today announced the publication in The Lancet Neurology of a key pivotal

read more >


Arvelle Therapeutics Strengthens Management Team with Key New Hires

Appoints Petra Molan as Senior Vice President Commercial and Enrico Dolfini as Vice President Legal Counsel Full leadership team now in place ahead of planned Marketing Authorization Application submission for cenobamate in Europe in H1 2020 Zug, Switzerland, October 31, 2019 – Arvelle Therapeutics GmbH (“Arvelle”), an emerging biopharmaceutical company focused on bringing innovative treatments

read more >


Newly-Formed Arvelle Therapeutics Acquires Exclusive Rights from SK Biopharmaceuticals to Develop and Commercialize Cenobamate in Europe

Arvelle Therapeutics GmbH to provide SK Biopharmaceuticals an upfront payment of $100 million with future milestone potential of up to $430 million A new CNS-focused company, Arvelle received one of the largest initial financing commitments for a European-focused biopharmaceutical company from a global syndicate which includes NovaQuest Capital Management, Life Sciences Partners (LSP), BRV Capital

read more >


CONTACT

(888) 317-1041

Switzerland:
Baarerstrasse 14
6300 Zug
Switzerland